

# 50360

FULBRIGHT & JAWORSKI L.L.P.

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER  
PARTNER

INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

A REGISTERED LIMITED LIABILITY PARTNERSHIP


600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

February 19, 2002

FILE: FHCC:009US



CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 19, 2002	
Date	
	Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 10/025,199 "GENE TRANSFER IN CHICKEN BURSAL STEM CELLS" – Paul E. Neiman

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A2, C1-C10).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112321/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/cmb

Encl: as noted

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Paul E. Neiman

Serial No.: 10/025,199


Filed: December 18, 2001

For: GENE TRANSFER IN CHICKEN  
BURSAL STEM CELLS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: FHCC:009US/SLH



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 19, 2002	
Date	Steven L. Highlander

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112321/SLH.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: February 19, 2002

Form PTO-1449 (modified)

Atty. Docket No.  
FHCC:009US/SLHSerial No.  
10/025,199

List of Patents and Publications for Applicant's

Applicant  
Paul E. Neiman

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
December 18, 2001Group:  
UnknownU.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,470,726	11/28/95	Miller <i>et al.</i>	435	172.3	8/11/93
	A2	5,766,945	6/16/98	Miller	435	325	2/12/97

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Burns <i>et al.</i> , "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells," <i>Proc. Nat'l Acad. Sci. USA</i> , 90:8033-8037, 1993.
	C2	Eskola and Toivanen, "Effect of <i>in Ovo</i> treatment with cyclophosphamide on lymphoid system in chicken," <i>Cell. Immunology</i> , 13:459-471, 1974.
	C3	Landau <i>et al.</i> , "Packaging system for rapid production of murine leukemia virus vectors with variable tropism," <i>J. Virol.</i> , 66:5110-5113, 1992.
	C4	Lee <i>et al.</i> , "Role of Nr13 in regulation of programmed cell death in the bursa of fabricius," <i>Genes &amp; Development</i> , 13:718-728, 1999
	C5	Miller <i>et al.</i> , "Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus," <i>Proc. Nat'l Acad. Sci. USA</i> , 91:78-82, 1994
	C6	Miller <i>et al.</i> , "Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus," <i>J. Virol.</i> , 65(5):2220-2224, 1991.
	C7	Neiman <i>et al.</i> , "Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius," <i>Proc. Nat'l Acad. Sci. USA</i> , 88:5857-5861, 1991.
	C8	Thompson <i>et al.</i> , "The effect of alterations in <i>myc</i> gene expression on B cell development in the Bursa of fabricius," <i>Cell</i> , 51:371-381, 1987.

25114625.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)


Atty. Docket No.  
FHCC:009US/SLHSerial No.  
10/025,199

List of Patents and Publications for Applicant's

Applicant  
Paul E. Neiman

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
December 18, 2001Group:  
UnknownU.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C9	Yee <i>et al.</i> , "A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes," <i>Proc. Nat'l Acad. Sci. USA</i> , 91:9564-9568, 1994.
	C10	Yom <i>et al.</i> , "Genetic engineering of milk composition: modification of milk components in lactating transgenic animals," <i>Amer. J. Clin. Nutr.</i> , 58(suppl):299S-306S, 1993.

25114625.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*